Risk of Violations of, and Tighter Regulation Under, E-Commerce Laws
First written in FY2016. 2 of 3 entries say "Restated". Latest entry: FY2020.
The whole theme swung hardest in 2025: 6 of 29 companies on the "Worse" side.
50 other companies' latest entry also says "Restated".
- FY2020RestatedAnnual report
「If the Group violates these laws or regulations, customer confidence may decline as a result of damage to the Group's brand image. In addition, if legal regulations are tightened through amendments to existing laws or the enactment of new laws or regulations, the Group's business and performance may be affected.」
The effects on credibility and performance of violations of the Act against Unjustifiable Premiums and Misleading Representations, the Act on Specified Commercial Transactions, the Pharmaceutical and Medical Device Act, and other laws, as well as tighter regulation, continue to be disclosed. - FY2018RestatedAnnual report
「However, if the Group violates these laws or regulations, customer confidence may decline as a result of damage to the Group's brand image. In addition, if legal regulations are tightened through amendments to existing laws or the enactment of new laws or regulations, the Group's business and performance may be affected.」
The effects on credibility and performance of violations of the Act against Unjustifiable Premiums and Misleading Representations, the Act on Specified Commercial Transactions, the Pharmaceutical and Medical Device Act, and other laws, as well as tighter regulation, continue to be disclosed. - FY2016First statedAnnual report
「However, if the Group violates these laws or regulations, customer confidence may decline as a result of damage to the Group's brand image. In addition, if legal regulations are tightened through amendments to existing laws or the enactment of new laws or regulations, the Group's business and performance may be affected.」
The company identifies violations of the Act against Unjustifiable Premiums and Misleading Representations, the Act on Specified Commercial Transactions, the Pharmaceutical and Medical Device Act, and other laws, as well as tighter regulation resulting from legal amendments or new legislation, as risks.